Page 9 - ஸ்வ் ஆரோக்கியம் முதலீட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration April 7, 2021 Share Artios Pharma CEO Niall Martin, PhD Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios. The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets for use with its RLTs, which are designed to deliver targeted radiation to a specific subset of cancer cells with minimal effect on surrounding healthy cells.

New yorkUnited statesArix bioscienceArtios pharmaNiall martinMerck kgaSv health investorsIp groupMerck kgaaBabraham research campus in cambridgeNovarti radioligand therapiesAdvanced accelerator applicationsAbbvie venturesAndera partnersLife science partnersPfizer ventures